AI-Native Scoping Reviews & Evidence Mapping

This paper shows that PAD risk is driven mainly by smoking and diabetes, but is also strongly shaped by age, hypertension, dyslipidemia, inflammation, and social disadvantage. The full paper is worth reading because it makes clear which factors matter most, which newer risk signals are emerging, and why PAD is still too often missed despite its major impact on limb loss and cardiovascular death.

This paper shows that fasting diets are not just weight-loss strategies, but biologically active interventions that may improve macrovascular health through better arterial function, lower vascular inflammation, and ketone-linked protective mechanisms. It is worth reading because it also reveals the key clinical tension behind the field: vascular benefits are promising, but microvascular responses may diverge, making patient selection and endpoint interpretation crucial.

This review shows that PAD diagnostics are shifting beyond resting ABI toward a multimodal future: post-exercise testing, advanced imaging, biomarkers, and AI repeatedly signal earlier and more precise detection, especially in patients where standard methods fail, such as those with diabetes. Read the full paper to see which emerging tools look truly promising, where the evidence is strongest, and which “innovations” still lack the validation needed for routine practice.

This paper shows that DVT is rarely a single-trigger event, but the end result of converging risks spanning infection, cancer, hormones, catheters, surgery, genetics, and inflammation. The full paper is worth reading because it reveals which risk factors carry the strongest clinical signal, how they cluster in real patients, and where prevention can most realistically stop thrombosis before it becomes PE or post-thrombotic syndrome.

Diabetic foot is not just a wound problem but a high-stakes collision of neuropathy, ischemia, infection, and delayed care, with a median major amputation rate of 10.3% across the mapped evidence. This review shows where the strongest signals truly are: why multidisciplinary care can cut major amputations by up to 80%, which risk factors matter most, and which emerging diagnostics and regenerative therapies may actually change outcomes.

This paper shows that DCB is not just a technical upgrade over POBA, but a consistently stronger strategy for restenosis-prone vascular disease, with better patency and fewer repeat interventions across coronary ISR, femoropopliteal lesions, BTK disease, and dialysis access. The full paper is worth reading because it reveals where that advantage is most convincing, where technique and vessel preparation change the outcome, and how much of DCB’s real-world value lies in selecting the right lesion, not just the device.

This paper shows that carotid shunts are neither universally protective nor universally harmful: they can reduce stroke risk in selected high-risk carotid surgery patients, but they also introduce their own complications. It is worth reading because it maps when shunting may truly help, when it may be unnecessary, and how monitoring can guide a safer, more tailored surgical strategy.

This review shows where thrombolysis in DVT truly helps and where it does not: the clearest signal is in selected iliofemoral disease, where modern catheter-based clot removal may improve patency and reduce post-thrombotic syndrome, but only at the cost of real bleeding risk. Read the full paper to see which techniques look most promising, which patients benefit most, and where the evidence still breaks down.

This paper shows that CT angiography in carotid stenosis is not just about measuring narrowing: it can reveal plaque vulnerability, near-occlusion, carotid webs, and hidden stroke risk that standard stenosis thresholds may miss. It is worth reading because it maps where CT truly adds clinical value, where it can mislead, and how more structured CTA reporting could change decision-making.

This review shows that DVT is not just a problem of stasis — it is a biologically active inflammatory process driven by endothelial injury, platelet–leukocyte crosstalk, and NET-mediated immunothrombosis. Read the full paper to see which mechanisms are strongest, which patient phenotypes carry the clearest signals, and which emerging biomarkers and targets could reshape risk stratification and therapy.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.

The paper tackles one of endovascular medicine’s most controversial questions: whether DCBs truly carry a late mortality risk. Mapping 170 original studies, it shows why the feared signal largely fades in broader evidence, where comorbidity and indication matter more than the device itself — and reveals the few settings where uncertainty still remains.